| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
As an amino acid derivative, 3,5-Diiodo-D-tyrosine does not have a defined primary drug target in the context of therapeutic development. However, as a diiodinated tyrosine analogue, it may be used in research to study thyroid hormone biosynthesis, tyrosine metabolism, and enzyme-substrate interactions. Diiodotyrosine is an intermediate in the synthesis of thyroid hormones (T3 and T4). The D-configuration may influence the compound's interactions with enzymes and receptors compared to the L-enantiomer. The iodine substituents can modulate the compound's physicochemical properties, lipophilicity, and binding affinity. The compound can serve as a building block for synthesizing iodinated peptides.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies on amino acid derivatives, including this iodinated tyrosine analogue, have demonstrated their capacity to influence the release of anabolic hormones, modulate fuel availability for cellular activity, enhance mental performance under stress-related conditions, and prevent exercise-induced muscle damage. As a diiodotyrosine derivative, this compound may be used in cell-based assays to investigate thyroid hormone synthesis, tyrosine metabolism, and the effects of iodination on peptide stability and biological activity. The compound can also be utilized in studies examining the role of iodinated amino acids in thyroid function and hormone signaling. |
| ln Vivo |
In vivo studies on iodinated tyrosine derivatives have been conducted in the context of thyroid hormone research. As a diiodotyrosine analogue, this compound may be administered in animal studies to evaluate its effects on thyroid function, hormone synthesis, or metabolism. However, specific in vivo pharmacological data for this exact compound remains limited, as it is primarily supplied as a research chemical for peptide synthesis and thyroid hormone research rather than as a therapeutic agent. The compound may be used as a precursor or intermediate in the synthesis of thyroid hormone analogues.
|
| Enzyme Assay |
Non-cell-based enzyme or receptor binding assays for this compound typically involve studies with purified enzymes involved in thyroid hormone biosynthesis, such as thyroid peroxidase or deiodinases. Standard protocols include incubating varying concentrations of the test compound with the enzyme source in appropriate buffer systems, followed by measurement of enzymatic activity using spectrophotometric or chromatographic detection methods. The compound can be tested for its ability to act as a substrate or inhibitor for these enzymes. For peptide synthesis applications, the compound is evaluated in coupling reactions using standard peptide synthesis chemistry.
|
| Cell Assay |
Cell-based assays for this diiodotyrosine derivative typically utilize thyroid cell lines or other cell types to evaluate compound effects on thyroid hormone synthesis and signaling. Standard protocols involve culturing cells in appropriate media at 37°C in 5% CO₂, followed by treatment with varying concentrations of the compound (typically 0.1-100 μM) for 24-72 hours. Cell viability is assessed using MTT or LDH release assays. The compound's effects on hormone production can be measured using ELISA or radioimmunoassay. For peptide synthesis applications, the compound is used as a building block for synthesizing iodinated peptides.
|
| Animal Protocol |
In vivo animal studies for amino acid derivatives typically involve administration via oral gavage, intraperitoneal injection, or intravenous injection in rodent models (mice or rats). Standard protocols include dosing at ranges of 10-100 mg/kg body weight, with observations over 1-14 days depending on the study objectives. For studies evaluating the effects of iodinated tyrosine derivatives on thyroid function, animals may be administered the compound and monitored for changes in thyroid hormone levels, thyroid gland morphology, and metabolic parameters. Pharmacodynamic assessments may include blood sampling for hormone analysis, tissue collection for histopathological examination, and monitoring of body weight. All animal studies must comply with institutional ethical guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for this diiodotyrosine derivative can be inferred from structurally related compounds. As a medium-sized molecule (molecular weight 432.98 g/mol) with high lipophilicity due to the iodine substituents, it is expected to have moderate bioavailability. The iodine substituents may influence the compound's distribution and metabolism. The compound shows moderate solubility in organic solvents such as DMSO and limited aqueous solubility. For in vivo administration, formulations using suitable co-solvent systems may be employed. The compound should be stored as powder at -20°C for long-term preservation. Definitive PK parameters require formal studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for this specific compound are limited as it is supplied for research use only and not intended for human therapeutic applications. Iodinated compounds may have specific toxicity profiles related to iodine content and thyroid function disruption. Appropriate safety precautions should be observed during handling, including the use of personal protective equipment and work in well-ventilated areas. The compound may cause skin and eye irritation upon contact. Acute toxicity studies in animal models would be required to establish LD₅₀ values and no-observed-adverse-effect levels. For in vitro cytotoxicity assessment, the compound can be tested in mammalian cell lines using standard MTT or LDH release assays.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
3,5-Diiodo-D-tyrosine is a diiodinated tyrosine derivative featuring two iodine substituents at the 3 and 5 positions of the phenolic ring. Diiodotyrosine is an important intermediate in thyroid hormone biosynthesis. This compound is used as a building block in peptide synthesis for introducing diiodinated tyrosine residues into peptide sequences for studying thyroid hormone function and iodination effects. It is not an approved drug and has not undergone clinical trials; it is strictly for research purposes.
|
| Molecular Formula |
C9H9I2NO3
|
|---|---|
| Molecular Weight |
432.98
|
| Exact Mass |
432.867
|
| CAS # |
16711-71-0
|
| PubChem CID |
7059641
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
2.4±0.1 g/cm3
|
| Boiling Point |
410.5±45.0 °C at 760 mmHg
|
| Flash Point |
202.1±28.7 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.748
|
| LogP |
2.26
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
15
|
| Complexity |
227
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=C(C=C(C(=C1I)O)I)C[C@H](C(=O)O)N
|
| InChi Key |
NYPYHUZRZVSYKL-SSDOTTSWSA-N
|
| InChi Code |
InChI=1S/C9H9I2NO3/c10-5-1-4(2-6(11)8(5)13)3-7(12)9(14)15/h1-2,7,13H,3,12H2,(H,14,15)/t7-/m1/s1
|
| Chemical Name |
(2R)-2-amino-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3096 mL | 11.5479 mL | 23.0958 mL | |
| 5 mM | 0.4619 mL | 2.3096 mL | 4.6192 mL | |
| 10 mM | 0.2310 mL | 1.1548 mL | 2.3096 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
